Published in Psychopharmacology (Berl) on July 01, 2004
Emerging strategies for exploiting cannabinoid receptor agonists as medicines. Br J Pharmacol (2009) 2.23
Cannabinoid hyperemesis syndrome. Curr Drug Abuse Rev (2011) 1.75
Anxiogenic-like effects of chronic cannabidiol administration in rats. Psychopharmacology (Berl) (2011) 1.44
Synthetic and natural antioxidants attenuate cisplatin-induced vomiting. BMC Pharmacol Toxicol (2017) 1.40
Identification of a high-affinity binding site involved in the transport of endocannabinoids. Proc Natl Acad Sci U S A (2005) 1.30
Targeting the endocannabinoid system with cannabinoid receptor agonists: pharmacological strategies and therapeutic possibilities. Philos Trans R Soc Lond B Biol Sci (2012) 1.27
Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol (2012) 1.11
Regulation of nausea and vomiting by cannabinoids. Br J Pharmacol (2011) 1.10
Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol (2013) 1.08
The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology (Berl) (2007) 1.08
Regulation of nausea and vomiting by cannabinoids and the endocannabinoid system. Eur J Pharmacol (2013) 1.08
Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology (Berl) (2004) 1.01
Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharmacol (2010) 0.99
The FAAH inhibitor URB-597 interferes with cisplatin- and nicotine-induced vomiting in the Suncus murinus (house musk shrew). Physiol Behav (2009) 0.97
The nonpsychoactive cannabinoid cannabidiol inhibits 5-hydroxytryptamine3A receptor-mediated currents in Xenopus laevis oocytes. J Pharmacol Exp Ther (2010) 0.96
Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. Psychopharmacology (Berl) (2006) 0.93
Successful Treatment of Suspected Cannabinoid Hyperemesis Syndrome Using Haloperidol in the Outpatient Setting. Case Rep Psychiatry (2016) 0.93
Cannabinoid-Induced Hyperemesis: A Conundrum-From Clinical Recognition to Basic Science Mechanisms. Pharmaceuticals (Basel) (2010) 0.92
Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology (Berl) (2011) 0.88
Delta 9-tetrahydrocannabinol suppresses vomiting behavior and Fos expression in both acute and delayed phases of cisplatin-induced emesis in the least shrew. Behav Brain Res (2008) 0.88
Cannabinoid Hyperemesis Syndrome: Diagnosis, Pathophysiology, and Treatment-a Systematic Review. J Med Toxicol (2016) 0.86
Computerized detection and analysis of cancer chemotherapy-induced emesis in a small animal model, musk shrew. J Neurosci Methods (2011) 0.86
Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol (2013) 0.85
Cannabinoid hyperemesis syndrome: a case report and review of pathophysiology. Clin Med Res (2014) 0.85
Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats. Br J Pharmacol (2013) 0.83
A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping. Psychopharmacology (Berl) (2014) 0.82
Receptor mechanism and antiemetic activity of structurally-diverse cannabinoids against radiation-induced emesis in the least shrew. Eur J Pharmacol (2007) 0.82
Delineation of vagal emetic pathways: intragastric copper sulfate-induced emesis and viral tract tracing in musk shrews. Am J Physiol Regul Integr Comp Physiol (2014) 0.82
Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus. Br J Pharmacol (2013) 0.81
Mechanisms of Broad-Spectrum Antiemetic Efficacy of Cannabinoids against Chemotherapy-Induced Acute and Delayed Vomiting. Pharmaceuticals (Basel) (2010) 0.79
Novel dynamic measures of emetic behavior in musk shrews. Auton Neurosci (2013) 0.79
Effect of selective inhibition of monoacylglycerol lipase (MAGL) on acute nausea, anticipatory nausea, and vomiting in rats and Suncus murinus. Psychopharmacology (Berl) (2014) 0.79
Cannabinoid Hyper-emesis Syndrome: An Enigma. Indian J Psychol Med (2013) 0.79
The antiemetic interaction of Delta9-tetrahydrocannabinol when combined with tropisetron or dexamethasone in the least shrew. Pharmacol Biochem Behav (2008) 0.78
Anandamide transport inhibition by ARN272 attenuates nausea-induced behaviour in rats, and vomiting in shrews (Suncus murinus). Br J Pharmacol (2013) 0.77
Low-Dose Cannabidiol Is Safe but Not Effective in the Treatment for Crohn's Disease, a Randomized Controlled Trial. Dig Dis Sci (2017) 0.75
Single and combined effects of delta(9) -tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. Br J Pharmacol (2017) 0.75
Cannabinoids As Potential Treatment for Chemotherapy-Induced Nausea and Vomiting. Front Pharmacol (2016) 0.75
Universities and tobacco money. BMJ (2001) 2.85
Cannabinoids inhibit emesis through CB1 receptors in the brainstem of the ferret. Gastroenterology (2001) 2.03
Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) (2003) 1.50
5-HT3 receptor antagonists injected into the area postrema inhibit cisplatin-induced emesis in the ferret. Br J Pharmacol (1989) 1.42
Cannabinoid agonists inhibit the activation of 5-HT3 receptors in rat nodose ganglion neurons. J Neurophysiol (1995) 1.40
The cannabinoid agonist WIN55,212-2 suppresses opioid-induced emesis in ferrets. Anesthesiology (2001) 1.24
An efficient new cannabinoid antiemetic in pediatric oncology. Life Sci (1995) 1.20
Delta(9)-tetrahydrocannabinol and synthetic cannabinoids prevent emesis produced by the cannabinoid CB(1) receptor antagonist/inverse agonist SR 141716A. Neuropsychopharmacology (2001) 1.18
Anticipatory nausea and vomiting in the era of 5-HT3 antiemetics. Support Care Cancer (1998) 0.99
The emetic and anti-emetic effects of the capsaicin analogue resiniferatoxin in Suncus murinus, the house musk shrew. Br J Pharmacol (2000) 0.98
The pharmacology of the emetic response to upper gastrointestinal tract stimulation in Suncus murinus. Eur J Pharmacol (1996) 0.97
Delta-9-tetrahydrocannabinol differentially suppresses cisplatin-induced emesis and indices of motor function via cannabinoid CB(1) receptors in the least shrew. Pharmacol Biochem Behav (2001) 0.96
Serotonin 5-HT3 receptor antagonists prevent cisplatin-induced emesis in Cryptotis parva: a new experimental model of emesis. J Neural Transm (Vienna) (1998) 0.91
The cannabinoid CB1 receptor antagonist SR 141716A reverses the antiemetic and motor depressant actions of WIN 55, 212-2. Eur J Pharmacol (2001) 0.90
Anandamide, an endogenous cannabinoid receptor ligand, also interacts with 5-hydroxytryptamine (5-HT) receptor. Biol Pharm Bull (1998) 0.89
Variables associated with anticipatory nausea and vomiting in pediatric cancer patients receiving ondansetron antiemetic therapy. J Pediatr Psychol (1997) 0.89
Tetrahydrocannabinol (THC) interferes with conditioned retching in Suncus murinus: an animal model of anticipatory nausea and vomiting (ANV). Neuroreport (2001) 0.88
Selective blockade of cytotoxic drug-induced emesis by 5-HT3 receptor antagonists in Suncus murinus. Jpn J Pharmacol (1991) 0.88
Improvement of cisplatin-induced emesis and delayed gastric emptying by KB-R6933, a novel 5-HT3 receptor antagonist. Gen Pharmacol (1999) 0.87
Antiemetic activity of N-methyllevonantradol and nabilone in cisplatin-treated cats. J Clin Pharmacol (1982) 0.85
Neuronal responses to cannabinoid receptor ligands in the solitary tract nucleus. Eur J Pharmacol (1998) 0.83
Male/female differences in drug-induced emesis and motion sickness in Suncus murinus. Pharmacol Biochem Behav (1997) 0.82
Neuronal responses to delta 9-tetrahydrocannabinol in the solitary tract nucleus. Eur J Pharmacol (1996) 0.82
The anti-emetic activity of GK-128 in Suncus murinus. Eur J Pharmacol (1995) 0.80
Inhibition of cisplatin-induced emesis in the pigeon by a non-psychotropic synthetic cannabinoid. Eur J Pharmacol (1989) 0.80
Is delayed chemotherapy-induced emesis well managed in oncological clinical practice? An observational study. Support Care Cancer (2003) 0.79
Anticipatory nausea and vomiting associated with cancer chemotherapy. N Engl J Med (1982) 0.79
Cisplatin-induced emesis in the cat: effect of granisetron and dexamethasone. Eur J Pharmacol (2000) 0.77
Antiemetic efficacy of smoked marijuana: subjective and behavioral effects on nausea induced by syrup of ipecac. Pharmacol Biochem Behav (2001) 0.76
Non-psychotropic plant cannabinoids: new therapeutic opportunities from an ancient herb. Trends Pharmacol Sci (2009) 2.32
The endocannabinoid system and the brain. Annu Rev Psychol (2012) 2.26
Peripheral cannabinoid receptor, CB2, regulates bone mass. Proc Natl Acad Sci U S A (2006) 1.95
Attenuation of allergic contact dermatitis through the endocannabinoid system. Science (2007) 1.70
A novel synthetic, nonpsychoactive cannabinoid acid (HU-320) with antiinflammatory properties in murine collagen-induced arthritis. Arthritis Rheum (2004) 1.67
Human brain endothelium: coexpression and function of vanilloid and endocannabinoid receptors. Brain Res Mol Brain Res (2004) 1.59
Cannabidiol attenuates cardiac dysfunction, oxidative stress, fibrosis, and inflammatory and cell death signaling pathways in diabetic cardiomyopathy. J Am Coll Cardiol (2010) 1.56
Cannabidiol: an overview of some pharmacological aspects. J Clin Pharmacol (2002) 1.52
N-arachidonoyl L-serine, an endocannabinoid-like brain constituent with vasodilatory properties. Proc Natl Acad Sci U S A (2006) 1.52
Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology (Berl) (2003) 1.50
The novel cannabinoid CB1 receptor neutral antagonist AM4113 suppresses food intake and food-reinforced behavior but does not induce signs of nausea in rats. Neuropsychopharmacology (2007) 1.44
Inhibition of human neutrophil chemotaxis by endogenous cannabinoids and phytocannabinoids: evidence for a site distinct from CB1 and CB2. Mol Pharmacol (2007) 1.30
Non-psychoactive CB2 cannabinoid agonists stimulate neural progenitor proliferation. FASEB J (2006) 1.28
Cannabinoids in health and disease. Dialogues Clin Neurosci (2007) 1.28
CB1 cannabinoid receptors are involved in neuroprotection via NF-kappa B inhibition. J Cereb Blood Flow Metab (2005) 1.25
Cannabidiol protects against hepatic ischemia/reperfusion injury by attenuating inflammatory signaling and response, oxidative/nitrative stress, and cell death. Free Radic Biol Med (2011) 1.24
Cannabinoid CB1 receptor inverse agonists and neutral antagonists: effects on food intake, food-reinforced behavior and food aversions. Physiol Behav (2007) 1.22
Tetrahydrocannabinol and endocannabinoids in feeding and appetite. Pharmacol Ther (2002) 1.20
The endocannabinoid 2-AG protects the blood-brain barrier after closed head injury and inhibits mRNA expression of proinflammatory cytokines. Neurobiol Dis (2005) 1.19
Cannabinoids provide neuroprotection against 6-hydroxydopamine toxicity in vivo and in vitro: relevance to Parkinson's disease. Neurobiol Dis (2005) 1.19
The CB(2) cannabinoid receptor controls myeloid progenitor trafficking: involvement in the pathogenesis of an animal model of multiple sclerosis. J Biol Chem (2008) 1.18
Endocannabinoids and traumatic brain injury. Br J Pharmacol (2011) 1.14
Cannabinoid CB2 receptor agonists protect the striatum against malonate toxicity: relevance for Huntington's disease. Glia (2009) 1.11
Milk intake and survival in newborn cannabinoid CB1 receptor knockout mice: evidence for a "CB3" receptor. Eur J Pharmacol (2003) 1.11
Cannabidiol arrests onset of autoimmune diabetes in NOD mice. Neuropharmacology (2007) 1.09
Cannabidiol for neurodegenerative disorders: important new clinical applications for this phytocannabinoid? Br J Clin Pharmacol (2013) 1.08
The effect of cannabidiol and URB597 on conditioned gaping (a model of nausea) elicited by a lithium-paired context in the rat. Psychopharmacology (Berl) (2007) 1.08
Cannabinoid receptor-dependent and -independent anti-proliferative effects of omega-3 ethanolamides in androgen receptor-positive and -negative prostate cancer cell lines. Carcinogenesis (2010) 1.08
Effect of Delta9-tetrahydrocannabinol on sucrose palatability as measured by the taste reactivity test. Physiol Behav (2005) 1.07
Drug-induced hypothermia reduces ischemic damage: effects of the cannabinoid HU-210. Stroke (2003) 1.07
Effects of cannabinoids on lithium-induced conditioned rejection reactions in a rat model of nausea. Psychopharmacology (Berl) (2003) 1.06
Chronic treatment with Delta-9-tetrahydrocannabinol alters the structure of neurons in the nucleus accumbens shell and medial prefrontal cortex of rats. Synapse (2006) 1.06
Evaluation of the neuroprotective effect of cannabinoids in a rat model of Parkinson's disease: importance of antioxidant and cannabinoid receptor-independent properties. Brain Res (2006) 1.06
Cannabinoids and endocannabinoids in metabolic disorders with focus on diabetes. Handb Exp Pharmacol (2011) 1.05
Noladin ether, a putative novel endocannabinoid: inactivation mechanisms and a sensitive method for its quantification in rat tissues. FEBS Lett (2002) 1.05
A new cannabinoid CB2 receptor agonist HU-910 attenuates oxidative stress, inflammation and cell death associated with hepatic ischaemia/reperfusion injury. Br J Pharmacol (2012) 1.04
The cannabinoid CB1 receptor regulates bone formation by modulating adrenergic signaling. FASEB J (2007) 1.04
Boswellia resin: from religious ceremonies to medical uses; a review of in-vitro, in-vivo and clinical trials. J Pharm Pharmacol (2009) 1.01
Involvement of neuronal cannabinoid receptor CB1 in regulation of bone mass and bone remodeling. Mol Pharmacol (2006) 1.01
Effect of low doses of delta9-tetrahydrocannabinol and cannabidiol on the extinction of cocaine-induced and amphetamine-induced conditioned place preference learning in rats. Psychopharmacology (Berl) (2004) 1.01
Cannabinoids: between neuroprotection and neurotoxicity. Curr Drug Targets CNS Neurol Disord (2005) 1.00
Prospects for cannabinoid therapies in basal ganglia disorders. Br J Pharmacol (2011) 1.00
Cannabinoids induce glioma stem-like cell differentiation and inhibit gliomagenesis. J Biol Chem (2007) 0.99
Incensole acetate, an incense component, elicits psychoactivity by activating TRPV3 channels in the brain. FASEB J (2008) 0.99
Oleoyl serine, an endogenous N-acyl amide, modulates bone remodeling and mass. Proc Natl Acad Sci U S A (2010) 0.99
Cannabidiol ameliorates cognitive and motor impairments in mice with bile duct ligation. J Hepatol (2009) 0.99
Delta-9-tetrahydrocannabinol and cannabidiol, but not ondansetron, interfere with conditioned retching reactions elicited by a lithium-paired context in Suncus murinus: An animal model of anticipatory nausea and vomiting. Physiol Behav (2005) 0.97
Cannabidiol, a nonpsychoactive Cannabis constituent, protects against myocardial ischemic reperfusion injury. Am J Physiol Heart Circ Physiol (2007) 0.97
Endocannabinoids affect neurological and cognitive function in thioacetamide-induced hepatic encephalopathy in mice. Neurobiol Dis (2005) 0.96
Incensole acetate: a novel neuroprotective agent isolated from Boswellia carterii. J Cereb Blood Flow Metab (2008) 0.96
N-arachidonoyl-L-serine is neuroprotective after traumatic brain injury by reducing apoptosis. J Cereb Blood Flow Metab (2011) 0.95
Cannabidiol reduced the striatal atrophy caused 3-nitropropionic acid in vivo by mechanisms independent of the activation of cannabinoid, vanilloid TRPV1 and adenosine A2A receptors. Eur J Neurosci (2007) 0.95
Double dissociation between regulation of conditioned disgust and taste avoidance by serotonin availability at the 5-HT(3) receptor in the posterior and anterior insular cortex. J Neurosci (2012) 0.95
Short-term fasting and prolonged semistarvation have opposite effects on 2-AG levels in mouse brain. Brain Res (2003) 0.94
Comparison of the enzymatic stability and intraocular pressure effects of 2-arachidonylglycerol and noladin ether, a novel putative endocannabinoid. Invest Ophthalmol Vis Sci (2002) 0.94
CB2 cannabinoid receptor targets mitogenic Gi protein-cyclin D1 axis in osteoblasts. J Bone Miner Res (2011) 0.94
5,7-dihydroxytryptamine lesions of the dorsal and median raphe nuclei interfere with lithium-induced conditioned gaping, but not conditioned taste avoidance, in rats. Behav Neurosci (2004) 0.94
N-Acyl amino acids and their impact on biological processes. Biofactors (2014) 0.93
Effects of the FAAH inhibitor, URB597, and anandamide on lithium-induced taste reactivity responses: a measure of nausea in the rat. Psychopharmacology (Berl) (2006) 0.93
Incensole acetate, a novel anti-inflammatory compound isolated from Boswellia resin, inhibits nuclear factor-kappa B activation. Mol Pharmacol (2007) 0.93
Exposure to a lithium-paired context elicits gaping in rats: A model of anticipatory nausea. Physiol Behav (2006) 0.93
Administration of 2-arachidonoylglycerol ameliorates both acute and chronic experimental autoimmune encephalomyelitis. Brain Res (2011) 0.93
A cannabinoid quinone inhibits angiogenesis by targeting vascular endothelial cells. Mol Pharmacol (2006) 0.92
Cannabidiol, a non-psychoactive component of cannabis and its synthetic dimethylheptyl homolog suppress nausea in an experimental model with rats. Neuroreport (2002) 0.92
Effects of THC on driving performance, physiological state and subjective feelings relative to alcohol. Accid Anal Prev (2007) 0.92
Cannabinoids ameliorate cerebral dysfunction following liver failure via AMP-activated protein kinase. FASEB J (2007) 0.91
FAAH inhibitor, URB-597, promotes extinction and CB(1) antagonist, SR141716, inhibits extinction of conditioned aversion produced by naloxone-precipitated morphine withdrawal, but not extinction of conditioned preference produced by morphine in rats. Pharmacol Biochem Behav (2009) 0.91
Endocannabinoids as positive or negative factors in hematopoietic cell migration and differentiation. Eur J Pharmacol (2008) 0.91
Evidence that (-)-7-hydroxy-4'-dimethylheptyl-cannabidiol activates a non-CB(1), non-CB(2), non-TRPV1 target in the mouse vas deferens. Neuropharmacology (2005) 0.91
Exposure to a context previously associated with nausea elicits conditioned gaping in rats: a model of anticipatory nausea. Behav Brain Res (2007) 0.91
HU-331, a novel cannabinoid-based anticancer topoisomerase II inhibitor. Mol Cancer Ther (2007) 0.90
Potential of the rat model of conditioned gaping to detect nausea produced by rolipram, a phosphodiesterase-4 (PDE4) inhibitor. Pharmacol Biochem Behav (2008) 0.89
Inhibition of monoacylglycerol lipase attenuates vomiting in Suncus murinus and 2-arachidonoyl glycerol attenuates nausea in rats. Br J Pharmacol (2012) 0.89
Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology (Berl) (2011) 0.88
Effect of delta9-tetrahydrocannabinol on quinine palatability and AM251 on sucrose and quinine palatability using the taste reactivity test. Physiol Behav (2006) 0.88
Skeletal lipidomics: regulation of bone metabolism by fatty acid amide family. Br J Pharmacol (2011) 0.88
Cannabinoids and capsaicin improve liver function following thioacetamide-induced acute injury in mice. Am J Gastroenterol (2008) 0.87
Synthesis and antitumor activity of quinonoid derivatives of cannabinoids. J Med Chem (2004) 0.87
Novel natural and synthetic ligands of the endocannabinoid system. Curr Med Chem (2010) 0.87
Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. Integr Physiol Behav Sci (2003) 0.87
Delta 9-tetrahydrocannabinol inhibits cell cycle progression by downregulation of E2F1 in human glioblastoma multiforme cells. Acta Oncol (2008) 0.86
Differential effects of neurotoxin-induced lesions of the basolateral amygdala and central nucleus of the amygdala on lithium-induced conditioned disgust reactions and conditioned taste avoidance. Behav Brain Res (2008) 0.86
The 5-HT1A agonist 8-OH-DPAT dose-dependently interferes with the establishment and the expression of lithium-induced conditioned rejection reactions in rats. Psychopharmacology (Berl) (2003) 0.85
Endocannabinoids in liver disease and hepatic encephalopathy. Curr Pharm Des (2008) 0.84
Effect of 5-HT3 antagonists and a 5-HT(1A) agonist on fluoxetine-induced conditioned gaping reactions in rats. Psychopharmacology (Berl) (2008) 0.83
N-arachidonoyl-L-serine (AraS) possesses proneurogenic properties in vitro and in vivo after traumatic brain injury. J Cereb Blood Flow Metab (2013) 0.83
Therapeutic opportunities through modulation of the endocannabinoid system. Neuropharmacology (2005) 0.83
Brain imaging study of the acute effects of Delta9-tetrahydrocannabinol (THC) on attention and motor coordination in regular users of marijuana. Psychopharmacology (Berl) (2007) 0.83
A comparison of cannabidiolic acid with other treatments for anticipatory nausea using a rat model of contextually elicited conditioned gaping. Psychopharmacology (Berl) (2014) 0.82
The synthetic cannabinoid HU-210 attenuates neural damage in diabetic mice and hyperglycemic pheochromocytoma PC12 cells. Neurobiol Dis (2007) 0.82
Increased liking for a solution is not necessary for the attenuation of neophobia in rats. Behav Neurosci (2010) 0.82
Extinction of a saccharin-lithium association: assessment by consumption and taste reactivity. Learn Behav (2006) 0.82
Cannabidiol, a constituent of Cannabis sativa, modulates sleep in rats. FEBS Lett (2006) 0.82
The nonpsychoactive Cannabis constituent cannabidiol is a wake-inducing agent. Behav Neurosci (2008) 0.81